UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
09 janv. 2019 13h15 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient...
Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
09 janv. 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a phase II...
Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
08 janv. 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient...
Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
07 janv. 2019 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael”), a leader in the field of cancer metabolism, today announced that Sanjeev Luther, President & CEO of Rafael...
Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
11 déc. 2018 08h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a phase...
Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
29 nov. 2018 09h10 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation...
Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613
06 nov. 2018 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Mike Stelmah as...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
15 oct. 2018 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals, Inc. will be presenting at the BIO Investor Forum 2018 in San Francisco...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
09 oct. 2018 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, its President...
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
16 août 2018 10h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S. Food and Drug...